Trial reportJournal of the American Heart Association2021
Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study.
Trial report in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 90 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- The effect of CoQ10 supplementation on cardiovascular risk factors in patients with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis.BMC pharmacology & toxicology · 2026Pooled it
- The modifying effect of diabetes on the association between triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular risk: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation.Frontiers in nutrition · 2025Pooled it
- Prevalence and Co-prevalence of Comorbidities among Patients with Type 2 Diabetes Mellitus in the MENA Region: A Systematic Review.Current diabetes reviews · 2024Pooled it
- Trajectories of Adherence to Study-Prescribed Physical Activity Goals in a mHealth Weight Loss Intervention.Sensors (Basel, Switzerland) · 2025Trial
- Effect of blood flow-restrictive resistance training on metabolic disorder and body composition in older adults with type 2 diabetes: a randomized controlled study.Frontiers in endocrinology · 2024Trial
- Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study.Journal of the American Heart Association · 2021Trial
- Divergent associations of TyG index and HOMA-IR with cardiovascular and cerebrovascular mortality in non-diabetic elderly: a competing risk analysis of NHANES 2003‒2020.Clinics (Sao Paulo, Brazil) · 2026Article
- Expression of APOL1 and NOTCH2 genes in patients with type 2 diabetes mellitus attending babcock University Teaching Hospital, Ogun State, Nigeria.Scientific reports · 2026Article
- Adissp activates insulin-independent glucose disposal and energy expenditure in white fat to treat diabetes and cardiometabolic disease.Science advances · 2026Article
- Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.Cardiovascular diabetology · 2026Review
- Prognostic value of triglyceride-derived metabolic parameters for micro- and macrovascular complications and mortality in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort study.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- A new insight on imaging characteristics of pericoronary adipose tissue for cardiovascular risk.Cardiovascular ultrasound · 2026Review
- Sex differences in LDL-C genetic architecture and statin efficacy in All of Us.medRxiv : the preprint server for health sciences · 2026Article
- Reframing glucolipid metabolic disorders through the lens of the oral microbiome: from pathophysiological mechanisms to translational potential.Frontiers in nutrition · 2026Review
- Atherogenic Index of Plasma is Independently Associated With Microalbuminuria in Type 2 Diabetes: A Retrospective Cross-Sectional Study.Journal of diabetes research · 2026Article
- Article
- Article
- High-density lipoprotein cholesterol levels and prognosis in non-ischemic dilated cardiomyopathy.Frontiers in endocrinology · 2026Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Background Metabolic dyslipidemia (high triglyceride) and low high-density lipoprotein cholesterol (HDL-C) is highly prevalent in type 2 diabetes mellitus (T2DM). The extent to which diabetes mellitus-related abnormalities in the triglyceride-HDL-C profile associates with cardiovascular disease (CVD) risk is incompletely understood. We evaluated the associations of triglyceride and HDL-C status with CVD outcomes in individuals with T2DM. Methods and Results We analyzed data from 4199 overweight/obese adults with T2DM free of CVD with available data on triglyceride and HDL-C at baseline (2001-2004) in the Look AHEAD (Action for Health in Diabetes) study. We used Cox proportional models to estimate hazard ratios (HRs) and 95% CIs of: (1) composite CVD outcome (myocardial infarction, stroke, hospitalization for angina, and/or death from cardiovascular causes); (2) coronary artery disease events; and (3) cerebrovascular accidents (stroke). Of the 4199 participants, 62% (n=2600) were women, with a mean age of 58 years (SD, 7), and 40% (n=1659) had metabolic dyslipidemia at baseline. Over a median follow-up of 9.5 years (interquartile range, 8.7-10.3), 500 participants experienced the composite CVD outcome, 396 experienced coronary artery disease events, and 100 experienced stroke. Low HDL-C was associated with higher hazards of the composite CVD outcome (HR, 1.36; 95% CI, 1.12-1.64 [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.